The estimated Net Worth of Helmy Eltoukhy is at least $483 Million dollars as of 30 June 2024. Mr. Eltoukhy owns over 11,462 units of Guardant Health Inc stock worth over $57,311,000 and over the last 6 years he sold GH stock worth over $424,897,952. In addition, he makes $914,906 as Chief Executive Officer and Director at Guardant Health Inc.
Helmy has made over 27 trades of the Guardant Health Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 11,462 units of GH stock worth $285,060 on 30 June 2024.
The largest trade he's ever made was exercising 565,192 units of Guardant Health Inc stock on 1 January 2021 worth over $14,056,325. On average, Helmy trades about 147,912 units every 61 days since 2018. As of 30 June 2024 he still owns at least 2,304,423 units of Guardant Health Inc stock.
You can see the complete history of Mr. Eltoukhy stock trades at the bottom of the page.
Helmy A. Eltoukhy Ph.D. serves as Chief Executive Officer, Director of the Company. Prior to founding our company, Dr. Eltoukhy held various positions at Illumina, Inc. from August 2008 to December 2012, including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. In June 2007, he co-founded Avantome Inc. to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing and served as Chief Executive Officer until its acquisition by Illumina in August 2008. He joined the Stanford Genome Technology Center as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the Stanford Genome Technology Center, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. He received his Ph.D., M.S. and B.S. degrees in electrical engineering from Stanford University.
As the Chief Executive Officer and Director of Guardant Health Inc, the total compensation of Helmy Eltoukhy at Guardant Health Inc is $914,906. There are 2 executives at Guardant Health Inc getting paid more, with Michael Wiley having the highest compensation of $2,216,070.
Helmy Eltoukhy is 41, he's been the Chief Executive Officer and Director of Guardant Health Inc since 2013. There are 14 older and 1 younger executives at Guardant Health Inc. The oldest executive at Guardant Health Inc is Stanley Meresman, 73, who is the Independent Director.
Helmy's mailing address filed with the SEC is 3100, Hanover Street, Palo Alto, Santa Clara County, California, 94306, United States.
Over the last 6 years, insiders at Guardant Health Inc have traded over $2,653,630,540 worth of Guardant Health Inc stock and bought 2,438,210 units worth $45,173,576 . The most active insiders traders include Bluebird (Cayman) Ltd Softb..., Bluebird (Cayman) Ltd Svf E..., and Helmy Eltoukhy. On average, Guardant Health Inc executives and independent directors trade stock every 6 days with the average trade being worth of $2,415,822. The most recent stock trade was executed by Kumud Kalia on 9 September 2024, trading 6,545 units of GH stock currently worth $162,774.
we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.
Guardant Health Inc executives and other stock owners filed with the SEC include: